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Abstract 
Review on t(3;5)(q26;q31) H2AFY/MECOM, with 
data on clinics, and the genes involved. 
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Clinics and pathology 
Disease 
Acute myelomonocytic leukaemia (M4-AML) 
Epidemiology 
Only one case to date, a 76-year-old male patient 
(Han et al., 2018). 
Evolution 
He achieved complete remission (CR), but he 
relapsed and died 10 months after diagnosis. 
Genes involved and 
proteins 
MECOM (Ecotropic Viral Integration 
Site 1 (EVI1) and Myelodysplastic 
Syndrome 1 (MDS1-EVI1) 
Location 3q26.2 
Note 
MECOM is a nuclear transcription factor that plays 
an essential role in the proliferation and maintenance 
of hematopoietic stem cells and can inhibit myeloid 
differentiation. Two alternative forms exists, one 
generated from EVI1, the other MECOM (MDS1 
and EVI1 complex locus) through intergenic splicing 
with MDS1 (myelodysplasia syndrome 1), a gene 
located 140 kb upstream of EVI1. 
Protein 
The protein encoded by this gene is a transcriptional 
regulator involved in cell differentiation and 
proliferation, and apoptosis. The encoded protein 
can interact with transcriptional coactivators 
(KAT2B (P/CAF), CREBBP (CBP)) and 
corepressors (CTBP1, HDAC) as well as other 
transcription factors (GATA1, SMAD3) (de 
Braekeleer et al., 2012) 




H2AFY codes for the proteins MACROH2A1. 
The first exon is non-coding. Due to alternative 
exons 6 (coding exons 5), coding for amino acids 
(aa) 198-226 or 229, there are 2 isoforms. Isoform 
MacroH2A1.1: 369 aa; 39,1 kDa; Isoform 
MacroH2A1.2: 372 aa, 39,6 kDa; This protein 
comprises a histone H2A domain (aa: 2-117; length: 
116 aa) with a HA2 signature: AGVIFPV (aa: 19-
25), a Lys-rich region (aa: 118-162; length: 45 aa) 
with a SQ-motif (aa 139-140) which can be 
phosphorylated by PIKKs, and a macro domain (aa: 
184-370; length: 187). Ubiquitination sites are at 
Lys115, Lys116 and Lys119 (Ogawa et al., 2005). 
Glycines (Gly224 and Gly314) are required for PAR 
(poly(ADP-ribose)) binding.  
MacroH2A1.1 is mainly found in differentiated, 
non-proliferative tissues, MacroH2A1.1 is 
upregulated in senescent cells; MacroH2A1.2 is 
more generally expressed, including in tissues with 
ongoing cell proliferation (Sporn and Jung 2012).  
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MACROH2A1 regulates gene transcription, DNA 
damage response, mitochondrial respiration and 
senescence.  
Methylations/acetylations MacroH2A1 is found on 
autosomes as part of facultative heterochromatin and 
is localized at two functionally distinct chromatin 
subtypes marked by trimethylation of histone H3 on 
lysine 27 (H3K27me3) or as part of transcriptionally 
active euchromatin marked by nine histone 
acetylations (H2B at K15 and K20; H3 at K4, K14 
and K18; H4 at K91; and H2A at K5) where it can 
either positively or negatively regulate transcription 
(reviewed in Ruiz and Gamble 2018).  
MacroH2A1.1-PARP1 axis Stressing signals 
generated during DNA damage repair, senescence, 
hormonal response, heat shock, or differentiation 
promote the binding of MacroH2A1.1 to activated 
PARP1 (poly(ADP-ribose) polymerase 1),  creating 
the macroH2A1.1-PARP1 axis. MacroH2A1.1 
recruit active PARP1 to chromatin and promotes the 
CREBBP -mediated acetylation of H2B K12 and 
K120, which either positively or negatively regulates 
the expression of MacroH2A1-target genes. On the 
other hand, when MacroH2A1.1 is highly expressed, 
MacroH2A1.1 can bind and inhibit PARP1 activity 
Chen et al., 2014; Hurtado-Bagès et al., 2018).  
MacroH2A1 regulates mitochondrial respiration 
MacroH2A1.1 reduces nuclear NAD+ consumption 
through PARP1 inhibition, allowing maintenance of 
mitochondrial NAD+ pools that are critical for 
respiration (Posavec Marjanovic et al., 2014).  
Epithelial-mesenchymal transition MacroH2A1.1 
isoform, but not MacroH2A1.2, can suppress EMT 
induction.  
Cancer Upregulation of mH2A1 induces SKP2 
subsequent CDK8 downregulation contributes to 
growth defect, G2/M arrest, polyploidy and tumour 
suppression in breast cancer (Xu et al., 2015). 
MacroH2A1.2, one of the MacroH2A isoforms (see 
above), has an intrinsic ability to inhibit breast 
cancer-derived osteoclastogenesis and prostate 
cancer-induced osteoclastogenesis. Overexpression 
of mH2A1.2, but not mH2A1.1, in breast cancer 
cells significantly increased ERBB2 expression and 
tumorigenicity (Li et al., 2012). Re-expression of 
MacroH2A1.1 suppressed cancer cell proliferation, 
anchorage-independent growth and cell invasiveness 
in breast cancer, and suppressed metastasis of 
melanoma through regulation of CDK8. Loss of 
MacroH2A1.1 was associated with cell growth and 
metastasis and a worse outcome in colon cancer. 
Conversely, MacroH2A1.2 levels have been found 
to be similar in all tumors independently of 
proliferation (Sporn and Jung 2012). Patients with 
low MacroH2A1.1 levels in lung tumor samples 
recur more likely. MacroH2A1 downregulation 
enhances the stem-like properties of bladder cancer 
cells. In contrast, in the claudin-low subtype of triple 
negative breast cancer (ESR1, PGR, normal ERBB2) 
presenting a high MacroH2A1.1 mRNA ratio exhibit 
a poor outcome, through epithelial-mesenchymal 
transition process towards metastatic development 
(Lavigne et al., 2014). 




5'H2AFY-3'MECOM. The breakpoint in 5q31.1 was 
located in intron 5 of H2AFY, and the breakpoint in 
3q26 was located in intron 1 of MECOM. H2AFY 
exon 5 was fused to MECOM exon 2 (Han et al., 
2018). 
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